Sanofi Pasteur is partnering with the Biomedical Advanced Research and Development Authority (BARDA) to develop a potential vaccine for the coronavirus COVID-19 that utilizes the same recombinant DNA platform used in its influenza vaccine Flublok and in its previous vaccine candidate for severe acute respiratory syndrome (SARS).
Announcing the collaboration in a 18 February press call, David Loew, Sanofi's global head of vaccines, said leveraging this previous...







